These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12503214)

  • 1. Multimodality treatment of metastatic renal cell carcinoma.
    Mickisch GH
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):681-5. PubMed ID: 12503214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urologic approaches to metastatic renal cell carcinoma.
    Mickisch GH
    Onkologie; 2001 Apr; 24(2):122-6. PubMed ID: 11441290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of renal cell carcinoma. A critical appraisal from a urologist's point of view.
    Mickisch GH
    Urol Int; 1999; 63(1):16-21. PubMed ID: 10592485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
    Kwan KG; Kapoor A
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
    Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
    Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of tumor nephrectomy in metastatic renal cell carcinoma].
    Scheepe JR; Mickisch GH
    Urologe A; 2002 May; 41(3):221-4. PubMed ID: 12132270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of surgery and immunotherapy in metastatic renal cell carcinoma.
    Mickisch GH; Mattes RH
    World J Urol; 2005 Jul; 23(3):191-5. PubMed ID: 15791469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
    Bex A; Horenblas S; de Gast GC
    Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz B; Belldegrun AS; Figlin RA
    Cancer; 2003 Jun; 97(12):2995-3002. PubMed ID: 12784334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presurgical therapy in metastatic renal cell carcinoma.
    Jonasch E
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):73-8. PubMed ID: 17187521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Debulking nephrectomy in metastatic renal cancer.
    Flanigan RC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive nephrectomy for metastatic renal cell carcinoma: is it still imperative in the era of targeted therapy?
    Pantuck AJ; Belldegrun AS; Figlin RA
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):693s-696s. PubMed ID: 17255295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection.
    Pantuck AJ; Zisman A; Dorey F; Chao DH; Han KR; Said J; Gitlitz BJ; Figlin RA; Belldegrun AS
    J Urol; 2003 Jun; 169(6):2076-83. PubMed ID: 12771723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multimodality treatment paradigms for renal cell carcinoma: surgery versus targeted agents.
    Köpke T; Bierer S; Wülfing C; Tiemann A; Hertle L; Herrmann E
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):763-71. PubMed ID: 19496713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel.
    Halbert RJ; Figlin RA; Atkins MB; Bernal M; Hutson TE; Uzzo RG; Bukowski RM; Khan KD; Wood CG; Dubois RW
    Cancer; 2006 Nov; 107(10):2375-83. PubMed ID: 17048248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of surgery and systemic therapy for renal cell carcinoma.
    Kenney PA; Wood CG
    Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
    Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.